143 related articles for article (PubMed ID: 25839889)
41. Vemurafenib-induced panniculitis.
Villani AP; Zaharia D; Dalle S; Depaepe L; Balme B; Thomas L
Eur J Dermatol; 2013 Apr; 23(2):258-60. PubMed ID: 23567624
[No Abstract] [Full Text] [Related]
42. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
Choe CH; McArthur GA; Caro I; Kempen JH; Amaravadi RK
Am J Ophthalmol; 2014 Oct; 158(4):831-837.e2. PubMed ID: 25036880
[TBL] [Abstract][Full Text] [Related]
43. A papulovesicular eruption in a man receiving chemotherapy for metastatic melanoma. Squamous syringometaplasia (squamous metaplasia) of the eccrine glands.
Wong P; Bangert JL; Levine N
Arch Dermatol; 1993 Feb; 129(2):232-3, 235-6. PubMed ID: 8434984
[No Abstract] [Full Text] [Related]
44. Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma.
Mangold AR; Bryce A; Sekulic A
J Am Acad Dermatol; 2014 Nov; 71(5):e205-6. PubMed ID: 25437992
[No Abstract] [Full Text] [Related]
45. Neutrophilic eccrine hidradenitis in two patients treated with BRAF inhibitors: a new cutaneous adverse event.
Herms F; Franck N; Kramkimel N; Fichel F; Delaval L; Laurent-Roussel S; Carlotti A; Avril MF
Br J Dermatol; 2017 Jun; 176(6):1645-1648. PubMed ID: 28005274
[TBL] [Abstract][Full Text] [Related]
46. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
[TBL] [Abstract][Full Text] [Related]
47. [Successful drug desensitization after vemurafenib-induced rash].
Klossowski N; Kislat A; Homey B; Gerber PA; Meller S
Hautarzt; 2015 Apr; 66(4):221-3. PubMed ID: 25698338
[TBL] [Abstract][Full Text] [Related]
48. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
49. Vemurafenib and radiosensitization.
Boussemart L; Boivin C; Claveau J; Tao YG; Tomasic G; Routier E; Mateus C; Deutsch E; Robert C
JAMA Dermatol; 2013 Jul; 149(7):855-7. PubMed ID: 23699661
[TBL] [Abstract][Full Text] [Related]
50. Early-Onset Vemurafenib-Induced DRESS Syndrome.
Munch M; Peuvrel L; Brocard A; Saint Jean M; Khammari A; Dreno B; Quereux G
Dermatology; 2016; 232(1):126-8. PubMed ID: 26418832
[TBL] [Abstract][Full Text] [Related]
51. Reaccion acneiforme noduloquistica secundaria a vemurafenib con buena respuesta a isotretinoina oralSevere acneiform eruption associated with vemurafenib with response to isotretinoin.
Elosua-Gonzalez M; Lopez-Estebaranz JL; Garcia-Zamora E; Vela-Ganuza M; Rodrigez-Vasquez X
Dermatol Online J; 2018 Aug; 24(8):. PubMed ID: 30677858
[TBL] [Abstract][Full Text] [Related]
52. Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature.
Vázquez-Osorio I; Sánchez-Aguilar MD; García-Rodiño S; Suárez-Peñaranda JM; Aliste C; Vázquez-Veiga H
Am J Dermatopathol; 2016 Jul; 38(7):e93-6. PubMed ID: 26959695
[TBL] [Abstract][Full Text] [Related]
53. Vemurafenib-induced bilateral facial palsy.
Shailesh FN; Singh M; Tiwari U; Hutchins LF
J Postgrad Med; 2014; 60(2):187-8. PubMed ID: 24823520
[TBL] [Abstract][Full Text] [Related]
54. Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan.
Uhara H; Kiyohara Y; Tsuda A; Takata M; Yamazaki N
Clin Transl Oncol; 2018 Feb; 20(2):169-175. PubMed ID: 28674996
[TBL] [Abstract][Full Text] [Related]
55. A model for cutaneous squamous cell carcinoma in vemurafenib therapy.
Kent R; Glorioso S; Nordberg ML
J La State Med Soc; 2012; 164(6):311-3. PubMed ID: 23431672
[TBL] [Abstract][Full Text] [Related]
56. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
57. Vemurafenib (Zelboraf) with longer follow-up. Metastatic melanoma: a few extra months of life, but many adverse effects.
Prescrire Int; 2015 Apr; 24(159):89-90. PubMed ID: 25941696
[TBL] [Abstract][Full Text] [Related]
58. Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial.
Fennira F; Pagès C; Schneider P; Sidina I; Viguier M; Basset-Seguin N; Madjlessi-Ezra N; Madelaine I; Bagot M; Battistella M; Porcher R; Mourah S; Lebbé C
Melanoma Res; 2014 Feb; 24(1):75-82. PubMed ID: 24241686
[TBL] [Abstract][Full Text] [Related]
59. Chemotherapy-induced eccrine squamous syringometaplasia in an infant.
Bittar PG; Casady M; Selim MA; Prose NS
Pediatr Dermatol; 2018 Jan; 35(1):e84-e85. PubMed ID: 29231256
[TBL] [Abstract][Full Text] [Related]
60. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
